Live Breaking News & Updates on California san diego moores cancer center

Stay updated with breaking news from California san diego moores cancer center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

Philadelphia , Pennsylvania , United-states , American , Brentl-wood , Susanm-obrien , Anjalis-advani , Aaront-gerds , Jeraldp-radich , Mark-litzow , Janel-liesveld , Matthew-wieduwilt

Combo Treatment Sans Chemotherapy Effective for Ph+ ALL Elderly

Combo Treatment Sans Chemotherapy Effective for Ph+ ALL Elderly
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United-states , Philadelphia , Pennsylvania , American , Mark-litzow , Matthew-wieduwilt , Ceciliacs-yeung , Ehabl-atallah , Anna-moseley , Susanm-obrien , Aaront-gerds , Megan-othus

Dr Bazhenova on Addressing Potential Gaps in the Treatment of Lung Cancer Care

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the hope to confirm a consensus on how to best move forward to address gaps in lung cancer care.

Lyudmilaa-bazhenova , California-san-diego-moores-cancer-center , Lung-cancer , Bridging-the-gaps-in-lung-cancer , Onclive-tv ,

Dr Bazhenova on Identifying Gaps in EGFR-Mutated Lung Cancer Care

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of collaborative efforts when approaching gaps in lung cancer care.

Lyudmilaa-bazhenova , California-san-diego-moores-cancer-center , Lung-cancer , Bridging-the-gaps-in-lung-cancer , Onclive-tv , Lung-cancer- ,

Dr Bazhenova on Treating Patients With Advanced NSCLC Harboring EGFR Mutations

Lyudmila A. Bazhenova, MD, discusses how to treat patients with non–small cell lung cancer who present with EGFR mutations, highlights how to accurately pinpoint gaps in lung cancer care, and expands on how to address these gaps in patients with non–small cell lung cancer.

Texas , United-states , Lyudmilaa-bazhenova , University-of-texas-md-anderson-cancer-center , California-san-diego-moores-cancer-center , Cancer-center , Precision-medicine-in-oncology , Onclive-tv , Lung-cancer ,

Dr Bazhenova on Potential Combination Strategies With KRAS G12C Inhibitors in Advanced NSCLC

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Lyudmilaa-bazhenova , Potential-combination-strategies-with , California-san-diego-moores-cancer-center , Adagrasib , Sotorasib , Kras-g12c-mutant-non-small-cell-lung-cancer , Shp2-inhibitors , Sos1-inhibitors , Scarlet-trial- , Kras-g12c-and-chemotherapy , Kras-g12c-and-immunotherapy

Petosemtamab Generates Early Clinical Activity and Tolerability in HNSCC

The bispecific antibody petosemtamab delivered responses with a manageable safety profile in patients with advanced head and neck squamous cell carcinoma.

Akamis-bio , Eli-lilly , Biotechn-replimune , Kinnate-biopharma , Ezra-cohen , Novartis , California-san-diego-moores-cancer-center , Pangea-therapeutics , Primmune-therapeutics , Head-amp-neck-cancers , News

Novel Bispecific Antibody Active in Recurrent/Metastatic Head and Neck Cancer

Responses in 37% of patients previously treated with anti-PD-1/L1 agents, platinum chemotherapy

United-states , Toronto , Ontario , Canada , American , Ezra-cohen , Lillian-siu , Charles-bankhead , Princess-margaret-cancer-centre , American-association-for-cancer-research , California-san-diego-moores-cancer-center , American-association

Dr Eskander on Pembrolizumab Plus Paclitaxel and Carboplatin in Endometrial Cancer

Ramez N. Eskander, MD, discusses findings from the phase 3 NRG GY018 trial of pembrolizumab plus chemotherapy in patients with endometrial cancer.

Ramezn-eskander , Reproductive-services , Department-of-obstetrics , Division-of-gynecologic-oncology , Gynecologic-oncology , California-san-diego-moores-cancer-center , D , University-of-california-san-diego-moores-cancer-center , Nrg-gy018-trial- , Pembrolizumab-plus-chemotherapy , Patients-with-endometrial-cancer

Research Shows Improved Progression-Free Survival for Endometrial Cancer with Pembrolizumab

Research Shows Improved Progression-Free Survival for Endometrial Cancer with Pembrolizumab
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Pennsylvania , United-states , Canada , Philadelphia , Ramez-eskander , National-clinical-trials-network , National-surgical-adjuvant-breast , National-cancer-institute , National-institutes-of-health , Data-monitoring-committee , Gynecologic-oncology-group , Merck-co-inc